Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| BLES Biochemicals Inc. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Implement surfactant (BLES®) replacement therapy using the Less Invasive Surfactant Administration technique in six tertiary institutions in Nigeria and evaluate its impact on 72-hour neonatal mortality in premature infants born less than 2000 grams at birth.
Background: In low- and middle-income countries (LMICs), respiratory distress syndrome (RDS) accounts for ~45% of all in-hospital neonatal mortality. Surfactant use is limited in LMICs, in part, due to the high cost, the lack of skill to perform laryngoscopy and tracheal intubation, and perhaps a perception that surfactant administration and mechanical ventilation must occur together. In LMICs, continuous positive airway pressure (CPAP) is often the highest mode of respiratory support available, and CPAP failure invariably means death. If Less Invasive Surfactant Administration (LISA) can reduce CPAP failure, as shown in high-income settings, it potentially can reduce prematurity-related neonatal mortality in LMICs. There are, however, no studies on how to safely implement LISA in LMICs. The LISA procedure is novel in LMICs; the procedure is not without risk (severe and minor), laryngoscopy is a difficult skill to acquire, master, and maintain, and the resource limitations in LMICs need consideration while implementing LISA.
Hypothesis: Compared to a historical control, introducing non-invasive surfactant administration through the less invasive surfactant administration (LISA) techniques will result in a relative risk reduction of all-cause 72-hour in-hospital mortality by at least 20%.
PICO Outline:
Population: Preterm infants </= 2 kg with respiratory distress defined by a Downes Respiratory Distress Score of >4, who are spontaneously breathing, and on CPAP.
Intervention: Surfactant administered through the less invasive surfactant administration (LISA), technique.
Comparator: A historical control of preterm babies </= 2 kg with respiratory distress defined by a Downes Respiratory Distress Score of >4, who are spontaneously breathing, and on CPAP.
Outcome measures:
Primary Outcome: 72-hour all-cause in-hospital mortality.
Secondary outcomes
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LISA Arm | Experimental | Eligible subjects who have respiratory distress syndrome (Anderson Silverman Score >4) managed on continuous positive airway pressure (CPAP) will receive surfactant via a thin catheter while on CPAP. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Surfactant | Drug | Laryngoscopy is performed, and BLES® surfactant is administered through BLEScath™ (a thin catheter) into the trachea to a spontaneously breathing preterm infant with respiratory distress syndrome who is being managed on CPAP |
| Measure | Description | Time Frame |
|---|---|---|
| 72-hour mortality | All cause mortality with 72-hours of life | 72 hours of life |
| Measure | Description | Time Frame |
|---|---|---|
| In-hospital mortality | All cause mortality during hospitalization | Through hospitalization, an average of 1 day to 10 weeks. |
| Difference in RDS score before and after the procedure. | Change in Anderson Silverman RDS Score before and after intervention (range: 0 to 10) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Osayame A Ekhaguere, MBBS, MPH | Indiana University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Federal Medical Center Asaba | Asaba | Delta | 11111 | Nigeria | ||
| University of Benin Teaching Hospital |
On request and approval from local principal investigators and ethical approval committee
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| D066087 | Perinatal Death |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D011248 | Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D013501 | Surface-Active Agents |
| ID | Term |
|---|---|
| D020313 | Specialty Uses of Chemicals |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided
Prospective cohort
Not provided
Not provided
Not provided
Not provided
|
| 6 hours post procedure |
| Benin City |
| Edo |
| 11111 |
| Nigeria |
| National Hospital Abuja | Garki | FCT Abuja | 11111 | Nigeria |
| Aminu Kano Teaching Hospital | Zaria | Kano State | 11111 | Nigeria |
| Lagos University Teaching Hospital. | Idi-Araba | Lagos | 11111 | Nigeria |
| University of Nigeria Teaching Hospital | Enugu | 11111 | Nigeria |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D003643 | Death |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |